ZLAB - Spark Newswire

2 minute read

Zai Lab Announces Phase 3 PRIME Study Of ZEJULA Met Its Primary Endpoint

Today, 5:05 PM

• PRIME study demonstrates that niraparib treatment had a clinically meaningful and statistically significant benefit in improving progression-free survival in the overall study population

ZLAB

1 minute read

Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates

By Vandana Singh

Today, 5:05 PM

Zai Lab Limited (NASDAQ:ZLAB) and Blueprint Medicines Corporation (NASDAQ:BPMC) have announced an exclusive collaboration and license agreement in Greater China, including mainland China,…

BPMC

3 minute read

Zai Lab And Blueprint Medicines Announce Strategic Collaboration And License Agreement For BLU-945 And BLU-701 In Greater China; Blueprint Medicines To Receive $25M Upfront Payment, Up To $590M In Potential Future Milestone Payments

By Benzinga Newsdesk

Today, 5:05 PM

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Blueprint Medicines Corporation (NASDAQ:BPMC) today announced an exclusive collaboration and license agreement for the development and commercialization of BLU-945 and

BPMC

21 minute read

Earnings Scheduled For November 9, 2021

By Benzinga Insights

Today, 5:05 PM

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

AAIC

3 minute read

ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof Of Concept In Phase 1b Psoriasis Study

By Benzinga Newsdesk

Today, 5:05 PM

Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque psoriasis; consistent

ZLAB

3 minute read

Zai Lab Highlights Data Out Of Its Partner, Entasis Therapeutics, Related To Topline Results From Sulbactam-Durlobactam Phase 3 ATTACK Trial

By Benzinga Newsdesk

Today, 5:05 PM

SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at Test of Cure vs.

ETTX

2 minute read

Geneseeq, Zai Lab Announce Strategic Collaboration To Advance Cancer Drug R&D

By Benzinga Newsdesk

Today, 5:05 PM

Geneseeq Technology Inc. ("Geneseeq") and Zai Lab, Ltd. ("Zai Lab") (NASDAQ:ZLAB)(HKEX: 9688) announce new strategic collaboration in Shanghai, China. The companies will collaborate to

ZLAB